METHYLPREDNISOLONE SODIUM SUCCINATE FOR INJECTION, USP POWDER FOR SOLUTION

Maa: Kanada

Kieli: englanti

Lähde: Health Canada

Aktiivinen ainesosa:

METHYLPREDNISOLONE; WATER

Saatavilla:

HOSPIRA HEALTHCARE ULC

ATC-koodi:

H02AB04

INN (Kansainvälinen yleisnimi):

METHYLPREDNISOLONE

Annos:

500MG; 10ML

Lääkemuoto:

POWDER FOR SOLUTION

Koostumus:

METHYLPREDNISOLONE 500MG; WATER 10ML

Antoreitti:

INTRAMUSCULAR

Kpl paketissa:

8ML

Prescription tyyppi:

Prescription

Terapeuttinen alue:

ADRENALS

Tuoteyhteenveto:

Active ingredient group (AIG) number: 0232014001; AHFS:

Valtuutuksen tilan:

CANCELLED POST MARKET

Valtuutus päivämäärä:

2019-04-05

Valmisteyhteenveto

_Pr_
_Methylprednisolone Sodium Succinate for Injection, USP- Product
Monograph _
_Page 1 of 35_
PRODUCT MONOGRAPH
P
R
M
ETHYLPREDNISOLONE
S
ODIUM
S
UCCINATE FOR
I
NJECTION
USP
Sterile Powder
500 mg, 1 g Vials
Glucocorticoid
Hospira Healthcare Corporation
17300 Trans-Canada Highway
Kirkland, Québec
H9J 2M5
Date of Revision: October 18, 2017
Submission Control No: 209610
_Pr_
_Methylprednisolone Sodium Succinate for Injection, USP- Product
Monograph _
_Page 2 of 35_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
........................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
...................................................................................................
5
WARNINGS AND PRECAUTIONS
.................................................................................
5
ADVERSE REACTIONS
.................................................................................................
15
DRUG INTERACTIONS
..................................................................................................
18
DOSAGE AND ADMINISTRATION
.............................................................................
25
OVERDOSAGE
................................................................................................................
28
ACTION AND CLINICAL PHARMACOLOGY
............................................................ 29
STORAGE AND STABILITY
.........................................................................................
31
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................. 31
PART II: SCIENTIFIC INFORMATION
...............................................................................
34
PHARMACEUTICAL INFORMATION
.........................................................................
34
CLINICAL TRIALS
..........